LIPOSOMAL ANTI-INFECTIVE FORMULATIONS TO INHIBIT NON-TUBERCULOUS MYCOBACTERIA (NTM) MICROAGGREGATE FORMATION AND ESTABLISHMENT OF NTM BIOFILM
Methods of treatment to prevent NTM microaggregate formation using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
1 . A method of inhibiting formation of microaggregates of nontuberculous mycobacteria (NTM), comprising:
administering to a patient a formulation comprising an antibiotic in unilamellar Liposomes.
2 . The method of claim 1 , wherein the liposomes are comprised of hydrogenated soy phosphatidylcholine (HSPC) and cholesterol.
3 . The method of claim 1 , wherein the liposomes are comprised of dipalmitoylphosphatidylcholine (DPPC) and cholesterol
4 . The method of claim 1 , wherein the liposomes have a mean diameter of 10 nanometers to 5.0 microns.
5 . The method of claim 1 , wherein the liposomes have a mean diameter of 50 to 300 nanometers.
6 . The method of claim 1 , wherein the antibiotic is ciprofloxacin.
7 . The method of claim 1 , comprising 20 to 80 mg/mL ciprofloxacin.
8 . The method of claim 1 , comprising 30 to 70 mg/mL ciprofloxacin.
9 . The method of claim 1 , comprising 40 to 60 mg/mL ciprofloxacin.
10 . The method of claim 1 , wherein the composition is aerosolized.
11 . The method of claim 1 , wherein particles of aerosolized have an aerodynamic diameter in the range of 0.5 to 12 microns.
12 . The method of claim 1 , wherein the aerosolized composition is inhaled into lungs of a human patient.
13 . The method of claim 1 , further comprising 40 to 100 mg/mL amikacin.
14 . The method of claim 1 , for use in inhibiting formation of microaggregates of nontuberculous mycobacteria (NTM) in biofilms.
15 . A method of treatment, comprising:
identifying a patient as susceptible to the formation of non-tuberculosis microbacteria (NTM) microaggregate formation; and
administering to the patient a formulation comprising a pharmaceutically acceptable carrier, free unencapsulated ciprofloxacin, and liposomal ciprofloxacin comprising 20 to 80 mg/mL ciprofloxacin in unilamellar liposomes comprised of cholesterol and hydrogenated soy phosphatidylcholine (HSPC).